Synthekine
9 known investors
Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy. Its pipeline targets cancer and inflammatory diseases.
BiotechHealthtech
Founders & leadership
KC
K. Christopher GarciaFounder
SM
Susan MolineauxCEO
MO
Martin OftChief Scientific Officer
NR
Naiyer RizviChief Medical Officer
G
GregoryChief Technical Officer
G
GeoffChief Business Officer
R
RobinChief Accounting and Administrative Officer
Investors · 9
Samsara BioCapital✓ verifiedPalo Alto
The Column Group✓ verifiedSan Francisco · $30M
Bain Capital Life SciencesBoston
Canaan PartnersStamford · $500K – $20M
RA CapitalBoston
TCG CrossoverPalo Alto
Deerfield Management CompanyreportedNew York
Janus Henderson InvestorsreportedLondon
Rock Springs CapitalreportedBaltimore
In the news
Frequently asked questions
- What does Synthekine do?
- Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy. Its pipeline targets cancer and inflammatory diseases.
- Who are Synthekine's investors?
- Synthekine's investors include Samsara BioCapital, The Column Group, Bain Capital Life Sciences, Canaan Partners, RA Capital, TCG Crossover, Deerfield Management Company, Janus Henderson Investors and 1 more.